Healthcare & Aging Society
7 companies
29.3% population aged 65+ (world highest). Healthcare spending 10.6% of GDP. Medical DX Promotion Plan: standardized EMRs at all institutions by 2030. Remote patient monitoring market 24.9% CAGR; patient monitoring market $2.2B → $3.3B by 2031. Hematology analyzers + reagents global market ~$10.2B in 2025 growing to $11.2B in 2026 (MarketsandMarkets). Global endoscopy devices market $61.9B in 2025 → $84.5B by 2034 (Straits Research). Japan dominates IVD instrumentation (Sysmex #1 globally in hematology) and GI endoscopy (Olympus ~70% global share). 2026-04-17 explore run added Fukuda Denshi (6960, patient-monitor duopoly with 6849), JMDC (4483, healthcare big-data peer to M3 via Omron), and PHC Holdings (6523, deep-value diabetes + EMR + diagnostics). 2026-05-04 explore run added Sysmex (6869, hematology global #1 with reagent annuity moat) and Olympus (7733, GI endoscopy ~70% global share — trough entry due to FDA Aizu import alert).
Recent Updates
Supply-chain/competitor exploration: added 3 stocks to thin Healthcare theme (2→5).
Updated: 6960.T, 4483.T, 6523.T
T-glass gap analysis: added Sysmex (hematology monopoly, #1 globally) and Olympus (GI endoscopy 70% global share). Fixed missing supply_chain entries for 6849.T and 2413.T.
Updated: 6869.T, 7733.T, 6849.T, 2413.T
Nihon Kohden (6849.T): FY2026 OpMar fell to 7.97% (miss). FY2027 +25.4% OP recovery guided. BEACON target reset needed. US expansion confirmed with FDA clearances. HOLD.
Updated: 6849.T
M3 (2413.T) evolved: FY2026 results confirmed re-acceleration, PE 19.4x, forward PE 17.9x, analyst +56% target.
Updated: 2413.T
Supply Chain Map
Drag nodes to rearrange. Hover to highlight connections. Click tracked companies to view details. Arrows show supplier → customer direction.
Peer Comparison
| Company | Ticker | Conv | PE | Fwd PE | P/B | ROE | Op Margin | D/E | Yield | FCF |
|---|---|---|---|---|---|---|---|---|---|---|
| Nihon Kohden Corporation | 6849.T | MEDIUM | 20.3 | 18.9 | 1.35 | 7.1% | 7.97% | 15.0% | 1.92% | N/A |
| M3, Inc. | 2413.T | MEDIUM | 19.4 | 17.9 | 2.4 | 12.2% | 20.9% | 42.0% | N/A | N/A |
| Fukuda Denshi Co., Ltd. | 6960.T | HIGH | 15.87 | 15.66 | 1.54 | 8.6% | 18.0% | 19.0% | 1.7% | +¥21B |
| JMDC Inc. | 4483.T | MEDIUM | 35.85 | 29.06 | 2.96 | 7.8% | 22.3% | 89.0% | 0.4% | +¥9B |
| PHC Holdings Corporation | 6523.T | MEDIUM | 38.5 | 10.71 | 0.85 | 0.6% | 6.2% | 248.0% | 3.9% | +¥32B |
| Sysmex Corporation | 6869.T | MEDIUM | 22.5 | — | ~3.0 (est.) | — | ~20% (est. from EBITDA 25.3%) | N/A | 2.6% | N/A |
| Olympus Corporation | 7733.T | MEDIUM | 22.98 | — | 3 | — | 18.9% (adj FY2025) | N/A | 1.45% | +¥109B (adj FY2025) |
Companies
Nihon Kohden Corporation
6849.TMEDIUMCore
Mean-reversion thesis: SLOWER than expected. FY2026: revenue +4.3% to ¥235.1B, but operating income FELL 9.5% to ¥18.7B (OpMar 7.97%, below target). O...
M3, Inc.
2413.TMEDIUMSatellite
FY2026 results confirmed re-acceleration thesis: revenue ¥351.4B (+23.3% YoY), OP ¥73.5B (+16.8%), NP ¥49.1B (+21.3%). FY2027 guidance: Revenue ¥400B ...
Fukuda Denshi Co., Ltd.
6960.THIGHCore
Duopoly-stability play in Japanese patient monitoring. Higher-quality peer to Nihon Kohden (6849): OpMar 17.97% vs 9.2%, FCF ¥20.5B (7.3% FCF yield), ...
JMDC Inc.
4483.TMEDIUMSatellite
Japan's largest private healthcare claims database, 54.57% owned by Omron (since Oct 2023). Q3 FY2026: revenue +23.2% YoY, OP +37.1%. Health Big Data ...
PHC Holdings Corporation
6523.TMEDIUMTactical
Deep-value turnaround. PB 0.85x (below book), 3.92% div yield, FCF ¥32B on ¥135B mcap = 23.6% FCF yield. StockAnalysis Forward PE 10.71x implies conse...
Sysmex Corporation
6869.TMEDIUMCore — IVD / Lab Equipment
Global #1 in hematology analyzers (~30% world share, 85% US market via CellaVision alliance, 65,000+ installed analyzers). Business model is an annuit...
Olympus Corporation
7733.TMEDIUMCore — Endoscopy / Surgical Devices
~70% global share in GI flexible endoscopy — a near-monopoly in a medical device category that every hospital with a GI department must have. Co-inven...